Here are some cliff notes on the new drug for use in the United States after it's FDA approval this week... welcome #pivmecillinam #Pivya !

idstewardship.com/drugs/pivmecil… #IDtwitter #IDxPosts

ACCP ID PRN and SIDP friends: if you’re presenting a poster or platform at MAD-ID The Antimicrobial Stewardship Meeting®️ in two weeks, let us know! 🥼🧪💊

Submit your info with the link below so we can share your exciting work with the rest of the ID world 🌎

forms.gle/2xbHJGBALDM7Qb…

Any article written by these 3 🌟s Sam Aitken Jason Pogue Ryan Shields is a must-read!
Growing threat of NDM-producing E. coli with penicillin-binding protein 3 mutations in the United States – is there a potential role for durlobactam? #IDXposts #NDM5 academic.oup.com/cid/article-ab…

Will this change how we treat UTIs in the US?

‼️FDA approved Pivya (pivmecillinam), an orally active prodrug of mecillinam for uncomplicated UTI!

Clinical cure & micro response 🧫 was 72% Pivya group vs 76% cephalexin
#IDtwitter #MedTwitter

fda.gov/news-events/pr…

In all of Monday’s madness, the European Commission approved Pfizer’s EMBLAVEO (aztreonam and avibactam combo) 💉

#IDtwitter #MedTwitter

pfizer.com/news/press-rel…

Don’t forget to stop at the grocery store before this fun event! 🍋‍🟩🍊

Join us as we whip up a fancy drink and chat with the best ID folks out there this Thursday!

📢Congratulations to Megan Shah! Thank you Dr. Shah for your dedication and significant contributions the profession of ID🦠

#IDtwitter #MedTwitter

Happy Earth Day 2024🌎 Let’s protect it while we can. Climate change:
1⃣ Increases disease given closer proximity of people & pathogens
2⃣ Changes tick/mosquito migration & 📈tickborne illnesses
#IDtwitter #MedTwitter

contagionlive.com/view/earth-day…

Outcomes of Ceftriaxone compared with Cefazolin OR Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Staphylococcus aureus (MSSA) BSIs - Results from a Large United States Claims Database

✍️ @igegeorgemd @washuid
🔗 bit.ly/3U6taAk

Artificial intelligence applications to infectious diseases are rapidly advancing. ID specialists can be prepared by learning about the benefits & limitations. Here are some practical use cases of generative #AI to support daily tasks in #antimicrobialstewardship . #SHEASpring2024

Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses

bit.ly/3U2pA8L

New #Breakpoints episode:

We invite you to the 1st ever meeting of The Tortured Stewards & Surgeons Department. Tune in to today’s episode to hear Drs. Patch Dellinger, DrTrishaPeel, and Michael Calderwood, MD, MPH discuss optimal management of perioperative antibiotics & prevention of SSI.

Managing ART for critically ill people with HIV in the ICU is complex. This review explores strategies for optimizing care amidst drug interactions and dosing challenges. Check it out for insights on improving outcomes: doi.org/10.1093/ofid/o…

A great summary on how to navigate the risk of opportunistic infections associated with long-term glucocorticoid use
doi.org/10.1093/cid/ci…
1⃣ Understand
2⃣ Assess risks
3⃣ Quantify risks
4⃣Prevention strategies
5⃣ Prioritize safety
6⃣ Assess future needs

Are hospital settings an untapped resource for potential HIV and HCV screening? 🤔

Hey ACCP ID PRN & SIDP members! Are you presenting at MAD-ID The Antimicrobial Stewardship Meeting®️ in May?! 🌴☀️🦠

Submit your poster/platform presentation information by May 3rd so we can recognize all your hard work! 🌟

🔗: forms.gle/2xbHJGBALDM7Qb…
#MADID2024 #IDXposts #IDTwitter

Don't forget about electing new officers for 2024-2025!

Renal Transplantation in HIV-positive and HIV-negative Patients with Advanced Stages of Kidney Disease: Equity in Transplantation

academic.oup.com/ofid/advance-a… #TxID

Talk about a triple-whammy‼️ Last week, the FDA approved ceftobiprole (Zevtera) for 🚨THREE🚨 indications:
1. S. aureus bacteremia 🩸
2. ABSSSI 💪
3. CABP 🫁

First beta lactam antibiotic FDA-approved for use in SAB 🦠💊

#IDtwitter #MedTwitter

fda.gov/news-events/pr…